43 matches for your search in the start-up spotlight
rss
Enhanc3D Genomics was spun out from the laboratories of Dr. Stefan Schoenfelder and Professor Peter Fraser, who pioneered research into the dynamic spatial organisation of the genome at the Babraham Institute in Cambridge, UK. Our mission is to unlock the full potential of the human genome’s 3D ...
Transine Therapeutics is developing a novel class of therapeutic RNAs that have the property to drive up protein expression with an unprecedented level of control and specificity: The SINEUP® platform. Our SINEUPs are designed to precisely bind to a target mRNA and boost expression of almost any ...
METiS Therapeutics is a discovery technology and therapeutics company that has the potential to drive best-in-class drug assets in a wide range of therapeutic areas. The METiS platform (AiTEM) combines state-of-the-art AI data-driven algorithms, mechanism-driven quantum mechanics and molecular ...
Evonetix is a Cambridge-based company developing a radically different approach to gene synthesis. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists’ ability to use biology on a scale not currently ...
Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. By using microchip industry materials and techniques we are revolutionizing in vitro research on cell models to help create better medicines, ...
Nuclera is driven by the mission to better human health by increasing accessibility to proteins. We are committed to providing rapid access to high-quality, soluble, active proteins at the benchtop allowing researchers to accelerate their protein projects, enabling faster success. Using ...
Cellino is on a mission to make personalized, autologous cell therapies accessible for patients. Stem cell-derived regenerative medicines are poised to cure some of the toughest diseases within this decade, including Parkinson’s, diabetes, and heart disease. Patient-specific cells provide the ...
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging ...
Echion Technologies supplies high-power Li-ion battery anode materials that enable superfast charging and low Total Cost of Ownership for the most demanding applications.
PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable' target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted' therapies more ...
